Athos Therapeutics is currently advancing two preclinical programs for patients with Ulcerative Colitis & Crohn’s Disease. Furthermore, Athos is pursuing additional discovery efforts against a range of validated and novel drug targets for patients with different autoimmune diseases and cancer.
(Moderate-to-severe, anti-TNFA refractory & colonic disease)
ATH-63 (Gene A)
(Moderate, anti-TNFA naive colonic & ileal disease)
ATH-105 (Gene B)
ATH-73 (Gene A)
ATH-XX (Gene A)
ATH-XX (Gene X)